Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amarin Corp. (AMRN) Misses Q3 EPS by 2c, Revenues Beat
February 27, 2019 5:59 AM ESTAmarin Corp. (NASDAQ: AMRN) reported Q3 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $77.33 million versus the consensus estimate of $73.87 million.
Net product revenue for the years ended December 31, 2018 and 2017 was $228.4 million and $179.8 million, respectively. Net product revenue for the three months ended December 31, 2018 and 2017 was $77.1 million and $53.5 million, respectively. Increased revenue is mainly attributed to increased Vascepa prescriptions in the U.S.In addition, Amarin recognized licensing revenue of $0.8 million and $1.3 million for the years ended December 31, 2018 and 2017, respectively, under... More